Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 6/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245529 | 0.88 | CHRNB4 (0.47) | CHRNB4CHRNA3CRHR1LIPCLIPG | |
| SCHEMBL12205232 | 0.86 | CNR2 (0.46) | CHRNB4CHRNA3CRHR1FLT3PIM1 | |
| SCHEMBL12205225 | 0.85 | APP (0.51) | CRHR1CHEK1FLT3PIM1 | |
| SCHEMBL12205337 | 0.82 | CHEK1 (0.41) | CHEK1PIM1 | |
| SCHEMBL12205189 | 0.80 | CRHR1 (0.39) | CRHR1CHEK1PIM1 | |
| SCHEMBL12205188 | 0.78 | CHRNB4 (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL12205338 | 0.77 | SYK (0.42) | PIM1 | |
| SCHEMBL4925453 | 0.74 | ROCK2 (0.45) | FLT3PIM1 | |
| SCHEMBL12205230 | 0.73 | APP (0.62) | HTR2C | |
| SCHEMBL12205340 | 0.71 | APP (0.46) | CHEK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | AC IMMUNE, S.A. (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-2377860-A1 | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | APP, PSEN1, PSEN2 | CHRNB4 193/4885CHRNA3 331/4885CRHR1 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.